These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 30089720)

  • 1. Requirement for MUC5AC in KRAS-dependent lung carcinogenesis.
    Bauer AK; Umer M; Richardson VL; Cumpian AM; Harder AQ; Khosravi N; Azzegagh Z; Hara NM; Ehre C; Mohebnasab M; Caetano MS; Merrick DT; van Bokhoven A; Wistuba II; Kadara H; Dickey BF; Velmurugan K; Mann PR; Lu X; Barón AE; Evans CM; Moghaddam SJ
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis.
    Dong Y; Zhou L; Zhao D; Li K; Liu Z; Che N; Liu H
    Jpn J Clin Oncol; 2020 Jun; 50(6):701-711. PubMed ID: 32083303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PKC
    Garg R; Cooke M; Benavides F; Abba MC; Cicchini M; Feldser DM; Kazanietz MG
    Cancer Res; 2020 Dec; 80(23):5166-5173. PubMed ID: 32994205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.
    Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
    Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
    Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
    Kim H; Kwon HJ; Park SY; Park Y; Park E; Chung JH
    PLoS One; 2018; 13(6):e0198634. PubMed ID: 29856861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma.
    Chalela R; González-García JG; Khilzi K; Curull V; Sánchez-Font A; Longarón R; Rodrigo-Calvo MT; Martín-Ontiyuelo C; Gea J; Bellosillo B
    Pathol Oncol Res; 2021; 27():598292. PubMed ID: 34257550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
    Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.
    Duruisseaux M; Antoine M; Rabbe N; Rodenas A; Mc Leer-Florin A; Lacave R; Poulot V; Duchêne B; Van Seuningen I; Cadranel J; Wislez M
    Lung Cancer; 2017 Jul; 109():92-100. PubMed ID: 28577958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
    Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
    Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
    Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YTHDF1 Promotes Cyclin B1 Translation through m
    Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
    Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K
    Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
    Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
    Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.